Ecabet sodium: A potential new agent in the management of distal colitis

Lawrance, Ian C.

doi:10.1111/j.1440-1746.2010.06339.x

J of Gastro and Hepatol

2010

DOI: 10.1111/j.1440-1746.2010.06339.x

|View full text |Cite

Ecabet sodium: A potential new agent in the management of distal colitis

Ian C. Lawrance

Abstract: See article in J. Gastroenterol. Hepatol. 2010; 25: 1259–1265

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

Lawrance¹

2014

WJG

View full text Add to dashboard Cite

The inflammatory bowel diseases (IBDs) are chronic incurable conditions that primarily present in young patients. Being incurable, the IBDs may be part of the patient's life for many years and these conditions require therapies that will be effective over the long-term. Surgery in Crohn's disease does not cure the disease with endoscopic recurrent in up to 70% of patients 1 year post resection. This means that, the patient will require many years of medications and the goal of the treating physician is to induce and maintain long-term remission without side effects. The development of the anti-tumour necrosis factor alpha (TNFα) agents has been a magnificent clinical advance in IBD, but they are not always effective, with loss of response overtime and, at times, discontinuation is required secondary to side effects. So what options are available if of the anti-TNFα agents can no longer be used? This review aims to provide other options for the physician, to remind them of the older established medications like azathioprine/6-mercaptopurine and methotrexate, the less established medications like mycophenolate mofetil and tacrolimus as well as newer therapeutic options like the anti-integins, which block the trafficking of leukocytes into the intestinal mucosa. The location of the intestinal inflammation must also be considered, as topical therapeutic agents may also be worthwhile to consider in the long-term management of the more challenging IBD patient. The more options that are available the more likely the patient will be able to have tailored therapy to treat their disease and a better long-term outcome.

show abstract

What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

Lawrance¹

2014

WJG

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Ecabet sodium: A potential new agent in the management of distal colitis

Abstract: See article in J. Gastroenterol. Hepatol. 2010; 25: 1259–1265

Cited by 1 publication

References 16 publications

What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

Contact Info

Product

Resources

About